Cancer Immunology, Immunotherapy

, Volume 58, Issue 8, pp 1265–1273

Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients

  • Valeska Hofmeister-Mueller
  • Claudia S. Vetter-Kauczok
  • Ramona Ullrich
  • Katharina Meder
  • Eugene Lukanidin
  • Eva-Bettina Broecker
  • Per thor Straten
  • Mads Hald Andersen
  • David Schrama
  • Juergen C. Becker
Open Access
Original Article

DOI: 10.1007/s00262-008-0640-0

Cite this article as:
Hofmeister-Mueller, V., Vetter-Kauczok, C.S., Ullrich, R. et al. Cancer Immunol Immunother (2009) 58: 1265. doi:10.1007/s00262-008-0640-0


S100A4 (metastasin 1) belongs to the S100 family of Ca2+ binding proteins. While not present in most differentiated adult tissues, S100A4 is upregulated in the micromilieu of tumors. It is primarily expressed by tumor-associated macrophages, fibroblasts, and tumor endothelial cells. Due to its strong induction in tumors S100A4 is a promising target for cancer immunotherapy. By reverse immunology, using epitope prediction programs, we identified 3 HLA-A1-restricted peptide epitopes (S100A4 A1-1, A1-2, and A1-3) which are subject to human T cell responses as detected in peripheral blood of melanoma patients by means of IFN-γ ELISPOT and cytotoxicity assays. In addition, IFN-γ responses to S100A4 A1-2 can not only be induced by stimulation of T cells with peptide-loaded DC but also by stimulation with S100A4 protein-loaded DC, indicating that this epitope is indeed generated by processing of the endogenously expressed protein. In addition, S100A4 A1-2 reactive T cells demonstrate lysis of HLA-A1+ fibroblasts in comparison to HLA-A1 fibroblasts. In summary, this HLA-A1-restricted peptide epitope is a candidate for immunotherapeutical approaches targeting S100A4-expressing cells in the tumor stroma.


CTL HLA-A1 epitope Melanoma Metastasin 1 S100A4 Tumor stroma 


S100A4, also referred to as metastasin 1 (mts1), fibroblast-specific protein 1 (FSP1), placental calcium-binding protein, CAPL, calvasculin, p9Ka, pEL-98, 18A2, or 42A belongs to the family of EF-hand calcium-binding proteins. S100A4 has both intracellular and extracellular functions. By binding to different target molecules S100A4 influences cell motility, invasion, adhesion, proliferation, apoptosis, remodeling of the extracellular matrix, and angiogenesis [15, 41]. S100A4 expression is enhanced under several pathological conditions including cancer, where it might be expressed in and released from tumor cells, tumor stroma cells or both [8, 48, 49]. Indeed, S100A4 expression was demonstrated in many cell types participating in formation of the tumor stroma, e.g., cancer-associated fibroblasts, tumor endothelial cells, and tumor-associated macrophages. Notably, an extensive study in breast cancer describes preferential expression of S100A4 in macrophages and fibroblasts [8]. All these stroma cells contribute to the development and progression of cancer by secretion of growth and angiogenic factors or extracellular matrix degrading enzymes leading to enhanced tumor cell proliferation, invasion, angiogenesis, and finally metastasis and in consequence are potential anti-cancer therapeutical targets [20, 21, 31]. S100A4 itself has been implicated in disease development and progression, as it promotes the oncogenic phenotype of tumor cells. Its expression has been described for a variety of cancer entities, e.g., carcinoma of the breast [12, 22, 30, 37, 46, 54], ovary [25], thyroid [23, 36, 57], esophagus [38], bladder [1, 11], gallbladder [9], colon [53], colorectum [10, 19], pancreas [2, 40, 45] and prostate [17], gastric cancers [14, 26, 55], lung [27, 34], and brain cancers [44, 52]. S100A4 expression has also been described in primary and metastatic melanoma [3, 32, 39]. Elevated S100A4 levels are associated with a more aggressive phenotype and a poor prognosis [11, 18, 26, 36]. Due to its involvement in disease development and progression and its broad expression in the tumor microenvironment, S100A appears as an attractive target for cancer therapy that should allow the destruction of the tumor directly by targeting the cancer cells themselves and indirectly by destroying the supporting tumor stroma cells. Indeed, the destruction of the tumor stroma may be essential to eradicate tumors [56].

Up to date, approaches for down-regulation of S100A4 expression by ribozymes [33] or RNA interference [51, 52] have demonstrated the feasibility of S100A4-directed anti-tumor therapies. For example, the reduction of its expression in a murine model of thyroid carcinoma was accompanied by enhanced sensitivity to chemotherapy [51]. To analyse if S100A4 may be a therapeutic target for cancer immunotherapy, we applied reverse immunology to identify S100A4-derived T cell epitopes and demonstrated their immunogenicity ex vivo as well as the occurrence of spontaneous immune responses against these in melanoma patients.

Materials and methods

Cells and cell lines

The HLA-A1+ lymphoblastoid cell line BM36.1 and the melanoma cell lines MelJuso, Mel2a, and Mel888 were cultured in RPMI 1640/10% FCS supplemented with 100 U penicillin/ml and 100 μg streptomycin/ml.

Human skin fibroblasts were isolated by incubation of normal skin tissue pieces obtained from the margins after resection of nevi or cancerous lesions in 0.25% collagenase (Collagenase D, Boehringer Mannheim, Mannheim, Germany) and 0.1 mg/ml DNAse. The resulting suspension was filtered through a fine mesh. Obtained cells were maintained in RPMI 1640 supplemented with 10% FCS.

After informed consent PBL were collected from HLA-A1+ patients (n = 16) with advanced malignant melanoma. PBL were isolated using Lymphoprep separation (Axis-Shield PoC AS, Oslo, Norway) according to the manufacturer’s instructions and used directly or after cryopreservation. PBL were cultured in RPMI 1640/10% human AB serum. CD8+ T cells were negatively selected using the CD8+ T Cell Isolation Kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s recommendations.

Dendritic cells were generated from PBL by adherence on culture dishes at 37°C for 60 min in RPMI 1640 enriched with 10% human AB serum. Adherent monocytes were cultured in RPMI 1640 supplemented with 10% human AB serum in the presence of IL-4 (1,000 U/ml) and GM-CSF (800 U/ml) for 6 days. DCs were matured by addition of IL1β (2 ng/ml), IL-6 (1,000 U/ml), TNFα (10 ng/ml), and PGE2 (1 μg/ml). The next day the resulting mature DC were pulsed with 10 μM peptide and 3 μg β2-microglobulin/ml overnight at 37°C. For loading of DC with S100A4 protein 1 × 106 immature DC/ml were incubated with 50 μg protein/ml overnight before adding the maturing cocktail.

Immunohistochemical staining

After pre-treatment with 0.1% pronase (Roche Diagnostics GmbH, Mannheim, Germany) for 20 min at 37°C and proteinase K (Dako, Hamburg, Germany) for 10 min at room temperature, respectively, paraffin sections of normal skin, nevi, and melanoma were stained with S100A4-specific rabbit antiserum or anti CD68 clone PG-M1 (Dako) and the appropriate DakoCytomation Envison+ Systems (Dako) followed by the Vector Nova red system (Vector Laboratories, Burlingame, USA) according to the manufacturer’s instructions. As negative control sections were stained with normal rabbit antiserum or without primary antibody, respectively.

S100A4 nonamer peptides

HLA-A1-restricted nonamer peptides derived from the full-length human S100A4 protein were selected using both SYFPEITHI [43] and BIMAS [42] peptide binding algorithms freely available via the internet ( and The peptides were synthesized by GenScript Corporation (Piscataway, New Jersey, USA). HLA-A1-restricted peptides derived from influenza nucleoprotein (NP) peptide 44–52 (CTELKLSDY) [13] were used as controls.

ELISPOT assays

The human IFN-γ ELISPOT assay was used to quantify peptide epitope-specific IFN-γ-releasing effector cells as described previously [5]. Briefly, nitrocellulose-bottomed 96-well plates (MultiScreen MAIP N45, Millipore GmbH, Schwalbach, Germany) were activated with 35% ethanol, washed with PBS, and coated with anti-IFN-γ Ab (1-D1K, Mabtech, Hamburg, Germany). The wells were washed and blocked by X-vivo medium (Cambrex Biosciences, Verviers, Belgium) before adding 1 × 104 stimulator BM36.1 cells loaded with or without 10 μM peptide and 3 × 105, 1 × 105, or 3 × 104 effector cells. To minimize background in samples stimulated with DC preincubated with S100A4 protein or peptides, only 1 × 105, 3 × 104, and 1 × 104 effector cells were used. After incubation overnight the wells were washed with PBS followed by addition of biotinylated secondary Ab (7-B6-1-Biotin, Mabtech, diluted in PBS/1% BSA). The plates were incubated for 2 h, washed, and streptavidin-enzyme conjugate (Streptavidin-ALP-PQ, Mabtech, diluted in PBS/1% BSA) was added. Incubation at room temperature for 1 h was followed by washing with wash buffer and substrate buffer (0.1 M NaCl, 50 mM MgCl2, 0.1 M Tris–HCl, pH 9.5), and addition of enzyme substrate NBT/BCIP (Mabtech). The reaction was stopped by washing with tap water upon the appearance of dark purple spots. Spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL Cellular Technology Ltd., Schwäbisch Gmünd, Germany). The peptide-specific CTL frequency was calculated from the numbers of spot-forming cells. All assays were performed at least in duplicates. To extend the sensitivity of the ELISPOT assay, PBL were stimulated once in vitro before analysis. At day 0, PBL were plated in a cell concentration of 1 × 106/ml in 6-well plates (Greiner GmbH, Frickenhausen, Germany) in X-vivo medium (Cambrex) supplemented with 10% heat inactivated human AB serum in the presence of 10 μM peptide (GeneScript Corporation). Alternatively, 1 × 105 irradiated (50 Gy) DC/ml loaded with S100A4 protein or peptide were used for stimulation of 1 × 106 PBL/ml in the presence of 40 U IL-2/ml (Proleukin, Chiron GmbH, Munich, Germany). IL-2 was added every 3–4 days to the culture. The cultured cells were tested for reactivity in ELISPOT on day 7.

Cytotoxicity assay

For the microcytotoxicity assay, 2 × 102 target cells/well were plated in Terasaki plates (Nunc, Wiesbaden, Germany) for 24 h. After 24 h, the in vitro prestimulated lymphocytes were added at effector:target ratios of 30:1 and 10:1 in a final volume of 10 μl [7]. After overnight incubation, the plates were washed, fixed with −20°C cold methanol, and stained with Giemsa-Solution (Merck, Darmstadt, Germany). All stained target cells were counted and the percent of lysis was calculated. As negative control target cells only, without adding effector cells, were used. In addition, specific lysis of fibroblasts or Mel2a was analysed in a 4 hour standard chromium release assay. Mel2a targets were preincubated with or without 10 μM peptide, 20 μg/ml W6/32 antibody (Dako, Hamburg, Germany), or IgG2a isotype control antibody (Dianova, Hamburg, Germany). Cold targets were preincubated with 10 μM S100A4 A1-2 or irrelevant peptide derived from influenza NP 44–52.

Sequence similarity search

A search for proteins containing the identified S100A4 peptides was done using the protein blast tool available at

Statistical analysis

Statistical analysis was performed using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego California USA,


S100A4 is upregulated in the tumor micromilieu

S100A4 upregulation in tumor and stroma cells has been demonstrated previously in a variety of cancers. Accordingly, immunohistochemical staining of normal skin and melanoma demonstrates that in situ expression of S100A4 in normal skin is absent or restricted to macrophages (Fig. 1a, e). Although in melanoma the extend of expression varied between patients (Fig. 1b, c), in addition to macrophages, cancer-associated fibroblasts, tumor endothelial cells, and melanoma cells themselves are S100A4+ (Fig. 1). No positive cells were detected in control stainings with normal rabbit serum. Notably, we also detected S100A4 protein expression in benign nevi (data not shown).
Fig. 1

S100A4 expression in the skin. Sections of normal skin (a, e) and primary melanoma (bd, fh) were stained with anti-S100A4 antiserum (ac, eg) or anti CD68 (d, h). ×10 (ad) and ×40 (eh)

Spontaneous IFN-γ responses to HLA-A1-restricted S100A4-derived peptide epitopes

The complete amino acid sequence of the human S100A4 protein consisting of 101 amino acids was searched for putative HLA class I binding peptides using the epitope prediction programs BIMAS [42] and SYFPEITHI [43]. Epitopes with SYFPEITHI scores >20 were found for HLA-A1, -A3, and -B8, whereas no high affinity peptides restricted to the HLA class I antigens HLA-A2, -B7, or -B27 were predicted. The highest score was reached for the HLA-A1-restricted peptides. Thus, we focussed on HLA-A1-restricted S100A4 epitopes in the further studies. In addition, the HLA-A1 allele is frequently expressed in the Caucasian population ( [35]. To this end, three HLA-A1-restricted nonamer peptides (S100A4 A1-1, S100A4 A1-2, and S100A4 A1-3) with scores >20 for SYFPEITHI were synthesized (Table 1, Fig. 2a). We tested for spontaneous CTL responses to these S100A4 epitopes ex vivo. Therefore, we scrutinized PBL from HLA-A1+ melanoma patients by IFN-γ ELISPOT. This analysis revealed, that in several patients IFN-γ responses to the three HLA-A1-restricted peptides were indeed detected (Fig. 2b, c).
Table 1

Position, amino acid sequence, and peptide binding prediction of HLA-A1-restricted S100A4 peptides





S100A4 A1-1




S100A4 A1-2




S100A4 A1-3




aThe higher the score the higher the affinity predicted

Fig. 2

HLA-A1-restricted S100A4 peptides and S100A4-directed IFN-γ immune responses. a In the amino acid sequence of the S100A4 protein the HLA-A1-restricted peptides S100A4 A1-1 (amino acid position 11–19: VMVSTFHKY), A1-2 (amino acid position 31–39: KSELKELLT), and A1-3 (amino acid position 67–75: DNEVDFQEY) were selected using epitope prediction programs. b IFN-γ ELISPOT responses of PBL of melanoma patients to S100A4 peptides A1-1, A1-2, and A1-3 after in vitro stimulation with S100A4 peptides are depicted as specific spots/105 cells = [mean spots+peptide − mean spots−peptide]. c Representative results of IFN-γ ELISPOTs are depicted as specific spots/3 × 105 cells (black columns), 1 × 105 cells (dark gray columns), and 3 × 104 cells (light gray columns). d 1 × 104 PBL of a melanoma patient prestimulated with DC loaded with S100A4 peptides A1-1, A1-2, or A1-3 (black columns) or with S100A4 protein (gray columns) were tested for their reactivity to S100A4 peptide-loaded DC in IFN-γ ELISPOT. e 1 × 105 (black columns) and 3 × 104 (gray columns) PBL of a melanoma patient were prestimulated with empty DC, DC incubated with S100A4 protein or DC loaded with the S100A4 A1-2 epitope. The IFN-γ response to the S100A4 protein and A1-2 epitope were analysed by ELISPOT

Peptide- versus protein-induced T cell responses

To further evaluate the immunogenicity of both S100A4 and the S100A4-derived peptides, we stimulated lymphocytes from HLA-A1+ donors in vitro with DC which where either given the possibility to process the whole protein or pulsed with the peptides. The response was measured by IFN-γ release ELISPOT assay to either protein or peptides. This analysis revealed that, in contrast to the epitopes S100A4 A1-1 and A1-3, IFN-γ responses to the peptide S100A4 A1-2 were not only induced by the respective peptides but also after in vitro stimulation using DC which processed the whole protein (Fig. 2d). The lack of IFN-γ response to the S100A4 A1-1 and A1-3 peptides after stimulation with S100A4 protein-loaded DC indicates that in this case no unspecific or CD4+ T cell responses were induced. This indicates that only the S100A4 A1-2 epitope is cross-presented and indeed generated by natural processing of the antigen, whereas the epitopes A1-1 and A1-3 albeit binding to HLA-A1 are not. Furthermore, after prestimulation with DC which processed S100A4 protein the IFN-γ release response to the complete S100A4 protein was significantly higher than in the response to the S100A4 A1-2 peptide indicating that other epitopes than the S100A4 A1-2 contribute to the anti S100A4 immune reaction (Fig. 2e). Although the majority of the additional immune response can likely be attributed to CD4+ T cells, it is also feasible that other MHC class I epitopes are cross-presented.

Cytotoxic activity of S100A4-specific T cells

The lytic capacity of S100A4-reactive CTL was tested in cytotoxicity assays. To this end, lymphocytes were stimulated with DC pulsed with S100A4 peptides A1-2, A1-3, or influenza NP peptide. Subsequently, lysis of peptide-loaded HLA-A1+ melanoma cell line MelJuso was evaluated (Fig. 3a). Notably, the target cells were either used directly or after pulse with the indicated peptides. All peptide-loaded target cells were similarly lysed by the activated lymphocytes. However, only lymphocytes stimulated with the naturally processed S100A4 peptide, i.e., S100A4 A1-2, were able to lyse the S100A4+ target cell without the additional peptide pulse; thus, confirming the earlier observation that only the S100 A4 A1-2 peptide epitope is suitable for S100A4 targeted immunotherapy. In order to test if S100A4 peptide-induced CTL would also recognize cancer-associated fibroblasts, we performed cytotoxicity assays against in vitro stimulated fibroblasts expressing S100A4. Confirming the prior analyses S100A4 A1-2 stimulated PBL lysed fibroblast much more effectively than S100A4 A1-1 and A1-3 stimulated PBL (Fig. 3b). Besides, lysis of HLA-A1+ fibroblasts by S100A4 A1-2-stimulated PBL was clearly superior as compared to HLA-A1 fibroblasts (Fig. 3b). To verify that lysis of S100A4+ target cells, e.g., Mel2a, is mediated at least in part by CD8+ T cells, a CD8+ enriched effector cell population was used. In blocking experiments lysis of target cells was reduced in the presence of the anti HLA-class I antibody W6/32 (Fig. 3c). In contrast, addition of isotype control antibody did not reduce target cell lysis (not shown). This Inhibition of lysis by blocking of MHC class I/TCR interaction demonstrated the MHC class I dependent cytotoxic activity (Fig. 3c). Furthermore, cold target inhibition experiments revealed that the T cells lysing the S100A4 expressing melanoma cells are the same that recognize the peptide-loaded target cells. Coincubation with the HLA-A1+, S100A4 cell line Mel888 loaded with S100A4 A1-2 significantly reduced lysis of hot targets by S100A4 1-2 stimulated CD8+ cells; in contrast, coincubation with cold targets loaded with the irrelevant influenza NP peptide 44-52 did not impair specific lysis (Fig. 3d).
Fig. 3

S100A4 directed cytotoxic activity of PBL of melanoma patients. All effector cells were obtained from melanoma patients. a PBL were stimulated with DC incubated with S100A4 peptides A1-2, A1-3 or control peptide derived from influenza NP. Lysis of peptide pulsed cells of the HLA-A1+ melanoma cell line MelJuso was analysed by cytotoxicity assays in effector to target ratios of 30:1 (black columns), and 10:1 (gray columns). b S100A4 A1-1, A1-2 or A1-3 peptide incubated DC were used to stimulate PBL. Lysis of HLA-A1+ and HLA-A1 fibroblasts was tested in cytotoxicity assays in effector to target ratios of 30:1. c CD8+ T cell enriched PBL were stimulated with DC loaded or not with S100A4 A1-2 peptide. Lysis of the HLA-A1+/S100A4+ melanoma cell line Mel2a, preincubated or not with W6/32, was analysed by cytotoxicity assay in effector to target ratios of 5:1 (black columns) and 2.5:1 (gray columns). d Lysis of Mel2a target cells by CD8+ T cells stimulated with S100A4 A1-2 peptide-loaded DC was analysed in an effector to target ratio of 10:1 in a cold target inhibition assay. The S100A4-, HLA-A1+ Mel888 cell line was incubated with the S100A4 1-2 epitope or an irrelevant control peptide and added as cold target in hot:cold ratios indicated

Comparison of S100A4-derived peptides with S100 family members

To estimate the risk of S100A4 peptide-directed therapies, the amino acid sequences of S100A4 family members were searched for the S100A4 A1-1, A1-2, and A1-3 epitopes and Blast searches were done for each of the identified S100A4 peptides. Apart from S100A4, no identical hit appeared for S100A4 A1-1 and only one other exact match, i.e., leukemia multidrug resistance associated protein, turned up for S100A4 A1-2 and A1-3 (Fig. 4).
Fig. 4

Alignment of human S100 proteins. Comparison of S100A4 with other S100 family members to detect homologies within the epitopes S100A4 A1-1, A1-2, and A1-3 sequences; shaded squares indicate amino acid identity. MRP Multidrug resistance associated protein


Melanoma is an immunogenic tumor, known to induce spontaneous immune responses which may result in partial regressions of primary tumors. This observation has led to the development of several immune therapeutic approaches including tumor specific vaccination. We have selected S100A4 as immunological target molecule and verified its upregulation in the tumor micromilieu of melanoma (Fig. 1). In addition, a correlation between S100A4 protein expression in melanoma and aggressive phenotype, especially in early superficial spreading melanomas, has been described [3]. Notably, in the presented report we characterized a HLA-A1-restricted peptide epitope, S100A4 A1-2, that is generated by processing of the complete S100A4 protein, demonstrated by reactivity to S100A4 protein-loaded DC, HLA-A1+ fibroblasts, and HLA-A1+ melanoma cells (Figs. 2 and 3). Interestingly, two other HLA-A1-restricted peptide epitopes were predicted by the used computer algorithms and ex vivo immune responses to these epitopes were detected in peripheral blood of melanoma patients, as well; however, when lymphocytes were stimulated with DC which processed the whole recombinant S100A4 protein only responses to one peptide, S100A4 A1-2, were induced. Vice versa only S100A4 A1-2 reactive T cells released IFN-γ in response to S100A4 processing DC or killed target cells without these being pulsed with peptide. This observation illustrates the limitations of reverse immunology and confirms the need for confirmation assays demonstrating the presentation of identified epitopes by the desired target cells, e.g., S100A4 A1-2 on fibroblasts or melanoma cells.

The presented results suggest that T cell responses to S100A4 A1-2 can be induced by vaccination, e.g., allowing the development of an immune therapy with a low risk of inducing immune escape variants since S100A4 is expressed both in melanoma cells as well as in the genetically relatively stable tumor stroma cells, which promote tumor progression. However, it has to be noted that S100A4 expression is not completely restricted to tumor cells and tumor stroma cells. Although S100A4 expression has not been detected in most normal tissues, e.g., obtained from the breast, colon, thyroid, kidney, and pancreas, its expression has been described for lymphoid organs and white matter astrocytes [16, 28]. Moreover, S100A4 is upregulated in injured tissues [4, 6, 29, 50]. Another concern regarding side effects is cross targeting of other S100 family members. The S100 proteins are widely expressed and fulfill diverse functions [47]. The amino acid identity of S100A4 and other S100 proteins is up to 61% (S100A2). However, Blast search for the S100A4 A1-2 peptide resulted in one other identical hit apart from S100A4 only, i.e., leukemia multidrug resistance associated protein (Fig. 4). Leukemia multidrug resistance associated protein has once been described so far, in the leukemia cell line HL60 [24]. Although predictable side effects using S100A4 A1-2 due to cross reaction with other S100A4 family members are low, possible adverse side effects of S100A4 targeting therapies have to be addressed in future studies.

In summary, S100A4 is an attractive target for anti-cancer therapy as its expression is elevated in the tumor micromilieu, both in tumor and tumor stroma cells. Hence, it is possible to develop strategies to simultaneously target different cell types contributing to tumor progression. The identification of an HLA-A1-restricted peptide derived from S100A4 will allow to investigate if active immunisation to S100A4+ cells is an feasible option for anti-cancer immunotherapy.


This work was funded by the Deutsche Forschungsgemeinschaft/DFG (KFO 124).

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Copyright information

© The Author(s) 2008

Authors and Affiliations

  • Valeska Hofmeister-Mueller
    • 1
  • Claudia S. Vetter-Kauczok
    • 1
  • Ramona Ullrich
    • 1
  • Katharina Meder
    • 1
  • Eugene Lukanidin
    • 2
  • Eva-Bettina Broecker
    • 1
  • Per thor Straten
    • 3
  • Mads Hald Andersen
    • 3
  • David Schrama
    • 1
  • Juergen C. Becker
    • 1
  1. 1.Department of Dermatology, Venerology and AllergologyUniversity of WuerzburgWürzburgGermany
  2. 2.Institute of Cancer Biology, Danish Cancer SocietyCopenhagenDenmark
  3. 3.Center for Cancer Immunotherapy (CCIT), Department of HematologyHerlev University HospitalHerlevDenmark

Personalised recommendations